Access to Guideline Concordant Care for Node-Positive Non-Small Cell Lung Cancer in the United States

To assess whether seeking care at multiple Commission on Cancer hospitals is associated with different rates of guideline-concordant care, 44,531 patients undergoing treatment for non-small cell lung cancer between 2004 and 2018 were analyzed. Visiting more than one Commission on Cancer hospital was associated with higher rates of guideline-concordant care for individuals with pN1 to pN2 lung cancer and higher overall survival at five years (54.35 percent vs 45.62 percent, P < .001).